U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Malignant Urinary System Neoplasm

MedGen UID:
1664391
•Concept ID:
C4725819
•
Neoplastic Process

Definition

Malignant urinary system neoplasm that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

Emerging drugs in the treatment of chronic cough.
Brister D, Wahab M, Rashad M, Diab N, Kolb M, Satia I
Expert Opin Emerg Drugs 2023 Dec;28(2):67-77. Epub 2023 Apr 24 doi: 10.1080/14728214.2023.2203912. PMID: 37060576
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
Motzer RJ, Taylor MH, Evans TRJ, Okusaka T, Glen H, Lubiniecki GM, Dutcus C, Smith AD, Okpara CE, Hussein Z, Hayato S, Tamai T, Makker V
Expert Rev Anticancer Ther 2022 Apr;22(4):383-400. Epub 2022 Apr 7 doi: 10.1080/14737140.2022.2039123. PMID: 35260027Free PMC Article
ACR Appropriateness Criteria(®) Hematospermia.
Expert Panel on Urologic Imaging:, Hosseinzadeh K, Oto A, Allen BC, Coakley FV, Friedman B, Fulgham PF, Hartman MS, Heller MT, Porter C, Sahni VA, Sudakoff GS, Verma S, Wang CL, Yoo DC, Remer EM, Eberhardt SC
J Am Coll Radiol 2017 May;14(5S):S154-S159. doi: 10.1016/j.jacr.2017.02.023. PMID: 28473071

Recent clinical studies

Etiology

Role of immunotherapy in bladder cancer.
Rhea LP, Mendez-Marti S, Kim D, Aragon-Ching JB
Cancer Treat Res Commun 2021;26:100296. Epub 2020 Dec 24 doi: 10.1016/j.ctarc.2020.100296. PMID: 33421822
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF
Ann Oncol 2019 Jun 1;30(6):970-976. doi: 10.1093/annonc/mdz127. PMID: 31050707Free PMC Article
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, Fléchon A, Gravis G, Hussain S, Takano T, Leng N, Kadel EE 3rd, Banchereau R, Hegde PS, Mariathasan S, Cui N, Shen X, Derleth CL, Green MC, Ravaud A
Lancet 2018 Feb 24;391(10122):748-757. Epub 2017 Dec 18 doi: 10.1016/S0140-6736(17)33297-X. PMID: 29268948
Renal cell carcinoma.
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V
Nat Rev Dis Primers 2017 Mar 9;3:17009. doi: 10.1038/nrdp.2017.9. PMID: 28276433Free PMC Article
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators
N Engl J Med 2017 Mar 16;376(11):1015-1026. Epub 2017 Feb 17 doi: 10.1056/NEJMoa1613683. PMID: 28212060Free PMC Article

Diagnosis

TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY
Eur Urol Oncol 2022 Dec;5(6):714-718. Epub 2022 Feb 23 doi: 10.1016/j.euo.2021.11.005. PMID: 35216942Free PMC Article
Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.
Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J
Clin Cancer Res 2021 Sep 15;27(18):5123-5130. Epub 2021 Jun 9 doi: 10.1158/1078-0432.CCR-20-4175. PMID: 34108177Free PMC Article
A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis.
Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, Tseng YY, Deasy R, Kost-Alimova M, Dančík V, Leshchiner ES, Viswanathan VS, Signoretti S, Choueiri TK, Boehm JS, Wagner BK, Doench JG, Clish CB, Clemons PA, Schreiber SL
Nat Commun 2019 Apr 8;10(1):1617. doi: 10.1038/s41467-019-09277-9. PMID: 30962421Free PMC Article
Renal cell carcinoma.
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V
Nat Rev Dis Primers 2017 Mar 9;3:17009. doi: 10.1038/nrdp.2017.9. PMID: 28276433Free PMC Article
Bladder cancer.
Morgan TM, Keegan KA, Clark PE
Curr Opin Oncol 2011 May;23(3):275-82. doi: 10.1097/CCO.0b013e3283446a11. PMID: 21311329

Therapy

Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.
Motzer RJ, Taylor MH, Evans TRJ, Okusaka T, Glen H, Lubiniecki GM, Dutcus C, Smith AD, Okpara CE, Hussein Z, Hayato S, Tamai T, Makker V
Expert Rev Anticancer Ther 2022 Apr;22(4):383-400. Epub 2022 Apr 7 doi: 10.1080/14737140.2022.2039123. PMID: 35260027Free PMC Article
CAR-T cells, from principle to clinical applications.
Bourbon E, Ghesquières H, Bachy E
Bull Cancer 2021 Oct;108(10S):S4-S17. doi: 10.1016/j.bulcan.2021.02.017. PMID: 34920806
Role of immunotherapy in bladder cancer.
Rhea LP, Mendez-Marti S, Kim D, Aragon-Ching JB
Cancer Treat Res Commun 2021;26:100296. Epub 2020 Dec 24 doi: 10.1016/j.ctarc.2020.100296. PMID: 33421822
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF
Ann Oncol 2019 Jun 1;30(6):970-976. doi: 10.1093/annonc/mdz127. PMID: 31050707Free PMC Article
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators
N Engl J Med 2017 Mar 16;376(11):1015-1026. Epub 2017 Feb 17 doi: 10.1056/NEJMoa1613683. PMID: 28212060Free PMC Article

Prognosis

Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient.
Lee HW, Chung W, Lee HO, Jeong DE, Jo A, Lim JE, Hong JH, Nam DH, Jeong BC, Park SH, Joo KM, Park WY
Genome Med 2020 May 27;12(1):47. doi: 10.1186/s13073-020-00741-6. PMID: 32460812Free PMC Article
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF
Ann Oncol 2019 Jun 1;30(6):970-976. doi: 10.1093/annonc/mdz127. PMID: 31050707Free PMC Article
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, Fléchon A, Gravis G, Hussain S, Takano T, Leng N, Kadel EE 3rd, Banchereau R, Hegde PS, Mariathasan S, Cui N, Shen X, Derleth CL, Green MC, Ravaud A
Lancet 2018 Feb 24;391(10122):748-757. Epub 2017 Dec 18 doi: 10.1016/S0140-6736(17)33297-X. PMID: 29268948
Renal cell carcinoma.
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V
Nat Rev Dis Primers 2017 Mar 9;3:17009. doi: 10.1038/nrdp.2017.9. PMID: 28276433Free PMC Article
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators
N Engl J Med 2017 Mar 16;376(11):1015-1026. Epub 2017 Feb 17 doi: 10.1056/NEJMoa1613683. PMID: 28212060Free PMC Article

Clinical prediction guides

Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS
Cancer 2022 Mar 15;128(6):1194-1205. Epub 2021 Dec 9 doi: 10.1002/cncr.34057. PMID: 34882781
Renal cell carcinoma.
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V
Nat Rev Dis Primers 2017 Mar 9;3:17009. doi: 10.1038/nrdp.2017.9. PMID: 28276433Free PMC Article
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators
N Engl J Med 2017 Mar 16;376(11):1015-1026. Epub 2017 Feb 17 doi: 10.1056/NEJMoa1613683. PMID: 28212060Free PMC Article
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL
J Clin Oncol 2010 Jul 1;28(19):3167-75. Epub 2010 Jun 1 doi: 10.1200/JCO.2009.26.7609. PMID: 20516446Free PMC Article
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group
J Clin Oncol 2008 Mar 1;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487. PMID: 18309951Free PMC Article

Recent systematic reviews

Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies.
Tafuri A, Smith DD, Cacciamani GE, Cole S, Shakir A, Sadeghi S, Vogelzang NJ, Quinn D, Gill PS, Gill IS
Clin Genitourin Cancer 2020 Oct;18(5):351-360.e3. Epub 2020 Jan 31 doi: 10.1016/j.clgc.2020.01.004. PMID: 32146152Free PMC Article
Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, Daugaard M, Presseau J, Thavorn K, Hutton B, Holt RA, Lalu MM
Transfus Med Rev 2019 Apr;33(2):98-110. Epub 2019 Feb 14 doi: 10.1016/j.tmrv.2019.01.005. PMID: 30948292
Transarterial Embolization of Angiomyolipoma: A Systematic Review.
Murray TE, Doyle F, Lee M
J Urol 2015 Sep;194(3):635-9. Epub 2015 Apr 25 doi: 10.1016/j.juro.2015.04.081. PMID: 25916674
Investigational therapies for non-muscle invasive bladder cancer.
Smaldone MC, Casella DP, Welchons DR, Gingrich JR
Expert Opin Investig Drugs 2010 Mar;19(3):371-83. doi: 10.1517/13543780903563372. PMID: 20078248
Will targeted therapy hold its promise? An evidence-based review.
Murdoch D, Sager J
Curr Opin Oncol 2008 Jan;20(1):104-11. doi: 10.1097/CCO.0b013e3282f44b12. PMID: 18043264

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...